文献速递乳腺癌

吡咯替尼联合卡培他滨对比拉帕替尼联合卡培他滨治疗HER2阳性转移性乳腺癌的PHOEBE三期试验

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-02-11

PHOEBE研究是一项在中国29家医院开展的多中心、开放标签、随机对照3期试验,纳入267例既往接受过曲妥珠单抗和紫杉类治疗的HER2阳性转移性乳腺癌患者,随机接受吡咯替尼或拉帕替尼联合卡培他滨治疗。

要点

  • 吡咯替尼联合卡培他滨较拉帕替尼联合卡培他滨显著延长无进展生存期。
  • 最常见≥3级不良事件为腹泻(吡咯替尼组31% vs 拉帕替尼组8%)和手足综合征(16% vs 15%)。
  • 该方案可作为曲妥珠单抗及化疗后HER2阳性转移性乳腺癌的替代治疗选择。

核心结论

  • 吡咯替尼联合卡培他滨较拉帕替尼联合卡培他滨显著改善无进展生存期,毒性可控,可作为曲妥珠单抗和化疗后的替代治疗选择。

研究设计与样本

  • 多中心、开放标签、随机对照3期试验,在中国29家医院开展,共267例患者随机分配。
  • 患者为病理确诊HER2阳性转移性乳腺癌,年龄18-70岁,ECOG体能状态0或1,既往接受过曲妥珠单抗和紫杉类治疗。
  • 随机按1:1分配至吡咯替尼400mg每日一次或拉帕替尼1250mg每日一次,联合卡培他滨1000mg/m²每日两次(每21天周期第1-14天),按激素受体状态和既往转移性疾病化疗线数分层。
  • 主要终点为盲态独立中心评估的无进展生存期,本次为预设中期分析。

主要发现

  • 最常见≥3级不良事件为腹泻(吡咯替尼组41例[31%] vs 拉帕替尼组11例[8%])和手足综合征(22例[16%] vs 20例[15%])。
  • 严重不良事件在吡咯替尼组报告14例(10%),拉帕替尼组11例(8%)。
  • 吡咯替尼组无治疗相关死亡,拉帕替尼组1例猝死被认为与治疗相关。

临床怎么用

  • 对于既往接受过曲妥珠单抗和化疗的HER2阳性转移性乳腺癌患者,可考虑吡咯替尼联合卡培他滨作为替代治疗方案。
  • 治疗期间需重点监测腹泻和手足综合征等不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine after previous trastuzumab. METHODS: This is an open-label, randomised, controlled, phase 3 trial done at 29 hospitals in China. Patients with pathologically confirmed HER2-positive metastatic breast cancer, aged 18-70 years, who had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had been previously treated with trastuzumab and taxanes were randomly assigned (1:1) to receive oral pyrotinib 400 mg or lapatinib 1250 mg once daily plus oral capecitabine 1000 mg/m2 twice daily on days 1-14 of each 21-day cycle. Randomisation was done via a centralised interactive web-response system with a block size of four or six and stratified by hormone receptor status and previous lines of chemotherapy for metastatic disease. The primary endpoint was progression-free survival according to masked independent central review. Efficacy and safety were assessed in all patients who received at least one dose of the study drugs. Results presented here are from a prespecified interim analysis. This study is registered with ClinicalTrials.gov, NCT03080805. FINDINGS: Between July 31, 2017, and Oct 30, 2018, 267 patients were enrolled and randomly assigned. 134 patients received pyrotinib plus capecitabine and 132 received lapatinib plus capecitabine. At data cutoff of the interim analysis on March 31, 2019, median progression-free survival was significantly longer with pyrotinib plus capecitabine (12·5 months [95% CI 9·7-not reached]) than with lapatinib plus capecitabine (6·8 months [5·4-8·1]; hazard ratio 0·39 [95% CI 0·27-0·56]; one-sided p<0·0001). The most common grade 3 or worse adverse events were diarrhoea (41 [31%] in the pyrotinib group vs 11 [8%] in the lapatinib group) and hand-foot syndrome (22 [16%] vs 20 [15%]). Serious adverse events were reported for 14 (10%) patients in the pyrotinib group and 11 (8%) patients in the lapatinib group. No treatment-related deaths were reported in the pyrotinib group and one sudden death in the lapatinib group was considered treatment related. INTERPRETATION: Pyrotinib plus capecitabine significantly improved progression-free survival compared with that for lapatinib plus capecitabine, with manageable toxicity, and can be considered an alternative treatment option for patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy. FUNDING: Jiangsu Hengrui Medicine and National Key R&D Program of China. TRANSLATIONS: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021. PMID: 33581774. doi:10.1016/S1470-2045(20)30702-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。